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HPP-CFU. In summary, the higher concentration cytokine com-
bination with IL-6 yielded more CD34 cells and more
CD34CD38-DR-cells in 14 days culture. CD34 cells expanded
in the presence of lower concentration cytokine combinations
present more differentiation character. IL-11 in either concentra-
tion resulted in a decrease in the progenitor cell numbers. At
present, the most promising cytokine combination appears to be
those containing IL-6 with high concentration cytokine combina-
tion. These ﬁndings help delineate the culture conditions that will
support the expansion of cord blood for adult transplantation.
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A NON-VIRAL METHOD OF TRANSFECTING MRNA FROM A NEURO-
BLASTOMA (NBL) CELL LINE (NGP) INTO IMMATURE DENDRITIC
CELLS (DC)
Stephan, B.S.2, Marie, O.2, Wei, H.2, Morris, K.1 1. Northwestern
University Feinberg School of Medicine, Chicago, IL; 2. Children’s
Memorial Hospital Stem Cell Laboratory, Chicago, IL
Background: DC are potent antigen presenting cells. mRNA
from a NGP cell line, combined with a cationic lipid, is a non-viral
method for transfecting immature DC. Method: To generate DC,
Peripheral Blood Mononuclear Cells (PBMC) were isolated using
Ficoll-Hypaque (Amersham Pharmacia) density gradient centrifu-
gation. CD 14 cells were puriﬁed using CD14 micro beads
(Miltenyi). 1  106 cells/ml were cultured for 7 days in AIM-V
media with 1 pen-strep (Gibco), 50ng/ml of hGM-CSF, and
50ng/ml of hIL-4 (Preprotech). mRNA was extracted from a neu-
roblastoma cell line (NGP) with the 
MACS mRNA isolation kit
(Miltenyi Biotech). DC were harvested and washed 2 with PBS.
Cells were loaded with 2
g of NGP mRNA using DMIER ac-
cording to the manufacturer’s protocol (Invitrogen). After 4 hours,
cells were washed 2 with PBS and phenotypic analysis of DC was
performed by ﬂow cytometry (Becton Dickinson FACSort). Cells
were stained with ﬂuorescein isothiocyanate (FITC)- or phyco-
erythrin (PE)-conjugated antibodies against CD45, CD14, CD80,
CD1a, CD83, CD86, DR, and CD11c for the expression of surface
markers characteristic of immature DC. Intracellular staining was
performed with GD2 (Chemicon) and CD56 antibodies after they
were ﬁxed and permeabilized. Results: The phenotype of DC
(negative for CD14 and strongly positive for CD45, CD11c, and
HLA-DR, dim positive for CD1a, CD80 and CD86 and negative
for CD83) showing the immature state of these cells. Twelve
experiments were done and in each experiment a median of 1 104
events were analyzed. A median of 2294 (range 493-7091) events
was gated. Demonstrating positivity for intracellular GD2 in a
median of 370 (range 210-2689) events. This represents a 30.4%
(range 5.4-65.4%) transfection efﬁciency when compared to the
positive control that demonstrated a median of 63.5% positive in
4181 events. Conclusions: We demonstrated the ability to trans-
fect NGP mRNA into Immature Dendritic cells with a non-viral
method achieving efﬁciencies of 30.4%. This step is one of many
in the development of a DC vaccine against neuroblastoma.
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ALTERED CD34 EXPRESSION OF UMBILICAL CORD BLOOD AFTER
THAWING
Shaw, P.H.1, Donnenberg, A.D.2, Zorich, G.P.1, Goyal, R.G.1 1. Uni-
versity of Pittsburgh School of Medicine, Pittsburgh, PA; 2. University of
Pittsburgh Cancer Institute, Pittsburgh, PA
There is good correlation between pre-freezing umbilical cord
blood (UCB) CD34 cell dose and engraftment in pediatric trans-
plant recipients. In our experience, when the cells from thawed and
washed UCB units are analyzed there is up to a 2-fold lower
recovery of CD34 cells than one would predict based upon
mononuclear cell recovery. This post-thaw CD34 cell dose
would appear insufﬁcient to engraft patients consistently, yet does
(data not shown). We hypothesize that CD34 expression is masked
immediately after thawing and is restored in short-term culture.
To test this, we analyzed the CD34 expression of cells in 5 thawed
and washed UCB units at the time of thawing, and at 12, 24 and 48
hours afterwards. The pre-freezing CD34 expression data was not
available as these UCB units were donated anonymously. The cells
from each experiment were seeded at a concentration of 1 105
cells/ml in 3ml of the following culture media in a 37C, 5% CO2
humidiﬁed incubator: phosphate-buffered saline (PBS) with 10%
bovine serum albumin (BSA) [control]; StemSpan (SS) liquid cul-
ture media (Stem Cell Technologies, Vancouver, BC, Canada)
with 10% BSA; and SS with 10% BSA and a four-cytokine com-
bination: thrombopoietin, Stem Cell Factor, Flt-3 ligand and In-
terleukin-3 (IL-3). The concentration of all cytokines was 50ng/ml
except IL-3 (100ng/ml). At the set time points, a cell count was
obtained and the cells were stained with the following monoclonal
antibodies: CD45 FITC, CD34 ECD, and CD3 PC5. The stained
cells were analyzed using a Beckman-Coulter FC500 cytometer.
An ISHAGE gating strategy was implemented to eliminate cells
with autoﬂuorescence or nonspeciﬁc antibody binding. Viability
(always  85%) and total cell counts did not signiﬁcantly change
during the time period studied in any of the culture conditions.
The mean starting % of cells expressing CD34 was 0.03%. By hour
12, all cultured cells showed a 10-fold increase in CD34 expression
(p  0.0005, paired t-test); there were no signiﬁcant differences
amongst the different culture conditions and CD34 expression did
not increase beyond 12 hours. Thus 12-hour culture of thawed
UCB restored the proportion of CD34 cells to within the re-
ported range for fresh specimens (0.1-0.5%). This could explain, in
part, why the engraftment characteristics of UCB units reﬂect their
pre-freezing CD34 content rather than immediately after thawing.
The exact mechanism of this shifting CD34 expression merits
further investigation.
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HEMATOPOIETIC STEM CELL (HSC) REDISTRIBUTION FOR CARDIAC
REPAIR FOLLOWING ACUTE MYOCARDIAL INFARCTION (AMI)
Atkins, H.1, Glover, C.2, Beanlands, R.2, Mostert, K.2, Miller, L.1,
Garrard, L.2, de Kemp, R.2 1. Ottawa Hospital, Ottawa, ON, Canada;
2. Ottawa Heart Institute, Ottawa, ON, Canada
Controversy surrounds the role of HSC in repairing cardiac
damage. In some animal studies, intracoronary or intramyocardial
injection of autologous HSC contributed to new myocardial tissue
following acute ischemic insult. The role of removing and rein-
jecting HSC is uncertain. HSC mobilized from the bone marrow
circulate widely. We hypothesize that circulating HSC can localize
to the area of revascularized cardiac damage following myocardial
infarction and that HSC engraftment may have a beneﬁcial effect
on cardiac function. A pilot trial was conducted to study the
feasibility and safety of HSC mobilization following AMI. Five
patients that experienced large transmural anterior AMIs received
4 daily subcutaneous injections of 10 ug/kg G-CSF. At presenta-
tion, all patients had high-grade occlusions of a coronary artery
that were successfully revascularized by percutaneous procedures.
Baseline cardiac bloodﬂow (rubidium-82 PET) and myocardial
metabolism (FDG-PET) studies conﬁrmed transmural infarction.
All patients started G-CSF within 7 days of AMI. Peripheral
venous blood contained a median of 1.7 CD34()cells per ul
(range 0.7 to 7.5) prior to G-CSF and a median of 75.6
CD34()cells per ul (range 72 to 91) following 4 days of G-CSF.
There was no toxicity associated with G-CSF administration. The
median baseline left ventricular ejection fraction (LVEj) was 30%
(range 23-40%). Four weeks following HSC mobilization, the
median LVEj increased to 40% (range 30 to 48%). This increase
was clinically and statistically signiﬁcant. Improvement in FDG
uptake and a trend for increased perfusion were also observed. We
conclude that administration of G-CSF following AMI is safe and
mobilizes HSC into the circulation. G-CSF is associated with
improved left ventricular function in a group of patients with large
anterior wall AMI, a greater improvement than would be expected
from historical controls. These ﬁndings suggest that G-CSF acts
directly upon the heart to trigger recovery or G-CSF mobilized
HSC migrate and engraft in the heart aiding recovery of cardiac
function. A larger, randomized trial is planned to explore these
issues.
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